N/A N=718 Effectiveness and Efficacy of Dynamic Optimal Timing, a Smart Phone App for Avoiding Pregnancy: an Observational Study
Desire to Avoid Pregnancy
Primary: Pregnancy Rates — 25 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=37 Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation
Leukemia, Myeloid, Acute
Primary: Composite Complete Remission (CRc) Rate After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML — 56.5; 33.3; 53.8…
Phase 2 N=33 Clinical Trial of Manganese-Enhanced MRI (MEMRI) to Assess Peri-Infarct Injury
ISCHEMIC CARDIOMYOPATHY
Primary: Infarct Size of MEMRI Versus DEMRI Scans — 12.2; 18.9 percentage of left ventricle — p=0.001
N/A N=295 Surgical Treatment of Aortic Stenosis With a Next Generation Surgical Aortic Valve
Aortic Valve Stenosis With Insufficiency · Aortic Valve Stenosis
Primary: Percent of Early Adverse Events — 1.7; 1.0; 4.5; 0.0 Percentage of subjects
N/A N=30 Effectiveness Trial for Evaluating IAHA for PFPS
Patellofemoral Pain Syndrome
Primary: Change in Visual Analog Scale (VAS) Score — 70; 62.23; 37.61; 25.025 millimeters
Phase 3 N=690 Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy
Pulmonary Arterial Hypertension
Primary: Time to First Clinical Worsening Event — 60.58; 49.31 weeks — p=0.0275
N/A N=70 Double-lumen Tubes (DLT) - Health Economic Study
Single Lung Ventilation · Thoracic Surgery · Anesthesia
Primary: Number of Times Bronchoscope is Used — 0.07; 3.14 Reported uses of bronchoscopes
N/A N=13 Effects of Transcutaneous Spinal Direct Current Stimulation in Incomplete Spinal Cord Injury
Incomplete Spinal Cord Injury
Primary: Percent Change in Hmax — 27.85; 8.43; -4.91; 16.20 percent change in Hmax
Phase 2 N=1 Effects of Leptin Replacement in Children
Obesity · Metabolic Syndrome · Diabetes
Primary: Weight — NA lbs
Phase 4 N=100 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
Acne Vulgaris
Primary: Number of Participants With Adverse Events (AE) — 5; 16 Participants
N/A N=2,543 Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Inflammatory Bowel Disease
Inflammatory Bowel Diseases · Ulcerative Colitis · Crohn's Disease
Primary: Disease Characteristics of Participants: Disease Duration — 63.0; 112.5; 120.0; 86.0 months
Phase 4 N=40 Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders
Autism Spectrum Disorders
Primary: Change From Baseline in Brain Activity During Task (Task-based fMRI) After a Single Dose of Nasal Spray — 0.11; -0.26; -0.15; -0.16 Change-from-baseline (BOLD response)
Phase 2 N=3 Effects of Human Leptin Replacement
Obesity · Metabolic Syndrome · Diabetes
Primary: Change in Weight — NA lbs
Phase 3 N=701 Optimization of the TB Treatment Regimen Cascade
Tuberculosis, Pulmonary
Primary: Tuberculose Treatment Outcome — 8; 8; 11; 5 Participants
N/A N=46 The VIBLOK SAfety and perFormancE Trial
HSV-2 Infection · Genital Herpes
Primary: Serious Adverse Device Effects — 0 Percentage SADE's